HCPCS Level II code J9045 denotes a 50 mg unit of carboplatin administered as an injectable chemotherapeutic agent. Carboplatin is widely used in oncology for several malignancies; accurate coding of units is critical for clinical documentation, billing, and aggregate drug utilization monitoring. Nationally, unit-based HCPCS codes for chemotherapy drugs like J9045 affect provider reimbursement, drug spending, and payer coverage policies.

Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for carboplatin administration, typical sites of service where the code is billed, and the payers commonly responsible for covering services billed with this code. The publication outlines benchmark elements and common billing considerations related to unit-based chemotherapy coding, and highlights where input for policy updates or payer-specific coverage rules may be relevant.

This summary is intended for billing managers, practice administrators, and policy analysts who need a national-level briefing on HCPCS Level II code J9045, including clinical purpose, billing context, and the payers typically involved.